Updated
Reviewed
Oct. 25, 2018
Appendix A: Key to Acronyms
General Terms
| Acronym | Definition |
|---|---|
| 17-BMP | beclomethasone 17-monopropionate |
| ADAP | AIDS drug assistance program |
| Ag/Ab | antigen/antibody |
| Al | aluminum |
| ALT | alanine aminotransferase |
| aOR | adjusted odds ratio |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| AUD | alcohol use disorder |
| AV | atrioventricular |
| AWP | average wholesale price |
| BID | twice daily |
| BMD | bone mineral density |
| BUN | blood urea nitrogen |
| Ca | calcium |
| CaCO3 | calcium carbonate |
| CAPD | chronic ambulatory peritoneal dialysis |
| CBC | complete blood count |
| CCB | calcium channel blockers |
| CD4 | CD4 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CI | confidence interval |
| CKD | chronic kidney disease |
| Cl | chloride |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CNS | central nervous system |
| CPK | creatine phosphokinase |
| Cr | creatinine |
| CrCl | creatinine clearance |
| CSF | cerebrospinal fluid |
| CV | cardiovascular |
| CVD | cardiovascular disease |
| CYP | cytochrome P450 |
| CYP3A4 | cytochrome P450 3A4 |
| DAA | direct-acting antiviral |
| DHA | dihydroartemisinin |
| DILI | drug-induced liver injury |
| DMPA | depot medroxyprogesterone acetate |
| DOT | directly observed therapy |
| EBV | Epstein-Barr virus |
| EC | enteric coated |
| ECG | electrocardiogram |
| eGFR | estimated glomerular filtration rate |
| FDA | Food and Drug Administration |
| FDC | fixed-dose combination |
| Fe | iron |
| FI | fusion inhibitor |
| FUL | federal upper limit |
| GAHT | gender-affirming hormone therapy |
| GAZT | azidothymidine glucuronide |
| GHB | gamma-hydroxybutyrate |
| GI | gastrointestinal |
| HAD | HIV-associated dementia |
| HAV | hepatitis A virus |
| HBcAb | hepatitis B core antibody |
| HBeAg | hepatitis B e antigen |
| HBsAb | hepatitis B surface antibody |
| HBsAg | hepatitis B surface antigen |
| HBV | hepatitis B virus |
| HCO3 | bicarbonate |
| HCV | hepatitis C virus |
| HD | hemodialysis |
| HDL | high-density lipoprotein |
| HIV | human immunodeficiency virus |
| HIV RNA | viral load |
| HIV-1 | human immunodeficiency virus type 1 |
| HIV-2 | human immunodeficiency virus type 2 |
| HIVAN | HIV-associated nephropathy |
| HLA | human leukocyte antigen |
| HMG-CoA | hydroxy-methylglutaryl-coenzyme A |
| HRT | hormone replacement therapy |
| HSR | hypersensitivity reaction |
| HTLV-1 | human T-lymphotropic virus-1 |
| INR | international normalized ratio |
| INSTI | integrase strand transfer inhibitor |
| IRIS | immune reconstitution inflammatory syndrome |
| K | potassium |
| KS | Kaposi’s sarcoma |
| LDL | low-density lipoprotein |
| LLOD | lower limits of detection |
| MAC | Mycobacterium avium complex |
| MAT | medication-assisted treatment |
| MATE | multidrug and toxin extrusion transporte |
| MDMA | methylenedioxymethamphetamine |
| Mg | magnesium |
| MI | myocardial infarction |
| MPA | medroxyprogesterone acetate |
| MRI | magnetic resonance imaging |
| msec | millisecond |
| MSM | men who have sex with men |
| MTR | multi-tablet regimen |
| Na | sodium |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRTI | nucleoside/nucleotide reverse transcriptase inhibitor |
| OAT | opioid agonist therapy |
| OATP | organic anion-transporting polypeptide |
| OCT2 | organic cation transporter 2 |
| OH-itraconazole | active metabolite of itraconazole |
| OI | opportunistic infection |
| ONDCP | Office of National Drug Control Policy |
| OR | odds ratio |
| OTP | opioid treatment program |
| OUD | opioid use disorder |
| PAH | pulmonary arterial hypertension |
| PCP | Pneumocystis jiroveci pneumonia |
| PCR | polymerase chain reaction |
| PDE5 | phosphodiesterase type 5 |
| PI | protease inhibitor |
| PI/c | cobicistat-boosted protease inhibitor |
| PI/r | ritonavir-boosted protease inhibitor |
| PK | pharmacokinetic |
| PO | orally |
| PPI | proton pump inhibitor |
| PR | protease |
| PrEP | pre-exposure prophylaxis |
| PTH | parathyroid hormone |
| q(n)d | every (n) days |
| q(n)h | every (n) hours |
| QTc | QT corrected for heart rate |
| RNA | ribonucleic acid |
| RR | relative risk |
| RT | reverse transcriptase |
| SAMHSA | Substance Abuse and Mental Health Services Administration |
| SCr | serum creatinine |
| SJS | Stevens-Johnson syndrome |
| SSRI | selective serotonin reuptake inhibitor |
| STI | sexually transmitted infection |
| STR | single-tablet regimen |
| SUD | substance use disorder |
| TB | tuberculosis |
| TCA | tricyclic antidepressant |
| TDM | therapeutic drug monitoring |
| TEN | toxic epidermal necrosis |
| TG | triglyceride |
| TID | three times a day |
| UGT | uridine diphosphate glucuronosyltransferase |
| VPA | valproic acid |
| WAC | wholesale acquisition cost |
| WHO | World Health Organization |
| XR | extended release |
| Zn | zinc |
Download Guidelines
- Section OnlyPDF (282.73 KB)
- Full GuidelinePDF (2.44 MB)
- Recommendations OnlyPDF (229.24 KB)
- Tables OnlyPDF (939.48 KB)